Your Health, We Care
Another NameNexavar、多吉美、索拉非尼
IndicationsIndicated for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and progressive differentiated thyroid cancer that is refractory to radioactive iodine therapy.
Specs
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
Sorafenib was initially approved in the United States in 2005, and the latest revised prescribing information is dated August 2023.
Indicated for adult patients with unresectable hepatocellular carcinoma, advanced renal cell carcinoma, or radioactive iodine-refractory differentiated thyroid cancer.
The recommended dosage is 400 mg twice daily, taken on an empty stomach.
Patients of reproductive potential should use effective contraception; no dose adjustment is required in elderly patients or those with mild to moderate hepatic or renal impairment.
Overdosage may present with diarrhea and skin reactions; discontinue the drug and provide supportive care.
After oral absorption, sorafenib is metabolized in the liver, with a half-life of approximately 25–48 hours.
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
